Beam Therapeutics (BEAM) Common Equity (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Common Equity data on file, last reported at $1.2 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 3.1% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 3.1% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 68.82% from the prior year.
• Common Equity for Q1 2026 stood at $1.2 billion, down from $1.2 billion in the prior quarter.
• Over the last five years, Common Equity for BEAM reached as high as $1.2 billion in Q4 2025 and fell as low as $714.5 million in Q3 2022.
• Historically, Common Equity has averaged $896.9 million across 5 years, with a median of $829.1 million in 2022.
• Across the five-year window, Common Equity surged 96.26% in 2022 and fell 25.25% in 2024, its largest moves.
• Year by year, Common Equity stood at $733.5 million in 2022, then jumped by 33.79% to $981.3 million in 2023, then decreased by 25.25% to $733.5 million in 2024, then surged by 68.82% to $1.2 billion in 2025, then retreated by 5.97% to $1.2 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $966.0 million in Q3 2025.